This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sherri Brown, MD
Amgen Center Thousand Oaks, CA 91320-1789 Mitzi Armstrong, RN, MN Thousand Oaks, Calif

Arch Dermatol. 1994;130(6):799.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The case presented by Samlaska and Noyes¹ in the May 1993 issue of the ARCHIVES of a patient who developed pruritus and erythematous edematous plaques at granulocyte colony-stimulating factor (G-CSF) injection sites is very interesting and unique with regard to the authors' conjecture at possible causation. The authors theorized that the skin reaction may have been due to impurities within a specific lot of G-CSF.

Filgrastim (G-CSF) is a sterile, clear, colorless, preservative-free liquid for parenteral administration produced by recombinant DNA technology. Product purity is determined by several assay methods designed to assess levels of potential contaminating DNA, protein, and endotoxins. Additionally, each lot of product is characterized by a number of assays that assess filgrastim integrity, identity, and activity. Assays and tests are performed using the most sophisticated technology available for the characterization of proteins. All methods are validated and approved by the Food and Drug Administration for . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?